UNITED THERAPEUTICS overview

Shareholder Alert: Ademi LLP investigates whether Miromatrix Medical Inc. has obtained a Fair Price in its transaction with United Therapeutics PR Newswire MILWAUKEE, Oct. 31, 2023 MILWAUKEE , Oct. 31, 2023 /PRNewswire/ -- Ademi LLP is investigating Miromatrix (Nasdaq: MIRO ) for possible breaches of fiduciary duty and other violations of law in its transaction with United Therapeutics . Click here to learn how to join the action https://www.ademilaw.com/case/Miromatrix-inc-0 or call Guri Ademi...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a biotechnology company with six FDA-approved therapies to address rare,...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022. “I’m thrilled that United Therapeutics continues to report double-digit revenue growth and our highest quarterly revenue ever,” said Martine Rothblatt , Ph.D., Chairperson and Chief Executive...

United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its second quarter 2023 financial results before the market opens on Wednesday, August 2, 2023. United Therapeutics will host a public webcast Wednesday, August 2, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations . A rebroadcast of the webcast will be available for one week and can be accessed at the same location....

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought against Liquidia Technologies, Inc. The Federal Circuit affirmed that Liquidia’s proposed Yutrepia™ product infringes a United Therapeutics’ patent, U.S. Patent No. 10,716,793 (the ’793 patent ). As a result, the U.S. Food and Drug...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, yesterday unveiled its new net zero energy distribution center located on the company’s co-headquarters campus in Research Triangle Park, North Carolina. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230614359824/en/ United Therapeutics Chairperson and CEO Martine Rothblatt delivers opening remarks at the company's Phase Five dedication ceremony. (Photo:...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022. “The hard work and determination of our over 1,000 Unitherians during the first quarter of this year allowed us to reach over $500 million in revenue for the second quarter ever,” said Martine...

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. United Therapeutics will host a public webcast Wednesday, May 3, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations . A rebroadcast of the webcast will be available for one week and can be accessed at the same location. United...